Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 21
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Functional structure of local connections and differentiation of cerebral cortex areas in the neonate

  • Pujol Nuez, Jesús|||0000-0002-9946-4547
  • Blanco Hinojo, Laura, 1981-
  • Persavento, C.
  • Martinez Vilavella, Gerard|||0000-0001-8948-4918
  • Falcon, Carles
  • Gascon, Mireia|||0000-0003-4537-8472
  • Rivas Lara, Ioar|||0000-0002-4743-619X
  • Vilanova, M.
  • Deus Yela, Juan|||0000-0002-3305-2662
  • Domingo Gispert, Juan
  • Gómez-Roig, María Dolores|||0000-0003-2329-1851
  • Llurba, Elisa|||0000-0003-4048-6407
  • Dadvand, Payam|||0000-0002-2325-1027
  • Sunyer Deu, Jordi|||0000-0002-2602-4110
Neuroimaging research on functional connectivity can provide valuable information on the developmental differentiation of the infant cerebral cortex into its functional areas. We examined healthy neonates to comprehensively map brain functional connectivity using a combination of local measures that uniquely capture the rich spatial structure of cerebral cortex functional connections. Optimal functional MRI scans were obtained in 61 neonates. Local functional connectivity maps were based on Iso-Distance Average Correlation (IDAC) measures. Single distance maps and maps combining three distinct IDAC measures were used to assess different levels of cortical area functional differentiation. A set of brain areas showed higher connectivity than the rest of the brain parenchyma in each local distance map. These areas were consistent with those supporting basic aspects of the neonatal repertoire of adaptive behaviors and included the sensorimotor, auditory and visual cortices, the frontal operculum/anterior insula (relevant for sucking, swallowing and the sense of taste), paracentral lobule (processing anal and urethral sphincter activity), default mode network (relevant for self-awareness), and limbic-emotional structures such as the anterior cingulate cortex, amygdala and hippocampus. However, the results also indicate that brain areas presumed to be actively developing may not necessarily be mature. In fact, combined distance, second-level maps confirmed that the functional differentiation of the cerebral cortex into functional areas in neonates is far from complete. Our results provide a more comprehensive understanding of the developing brain systems, while also highlighting the substantial developmental journey that the neonatal brain must undergo to reach adulthood.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications, a systematic review and meta-analysis

  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Vázquez, Juan Carlos
  • Ullmo, Johana|||0000-0002-9313-917X
  • Llurba, Elisa|||0000-0003-4048-6407
Background: Evidence on the impact of low-molecular-weight heparin, alone or in combination with low-dose aspirin, for the prevention for preeclampsia in high-risk patients is conflicting. Objective: We conducted a meta-analysis of studies published to assess the effectiveness of low-molecular-weight heparin for the prevention of preeclampsia and other placenta-related complications in high-risk women. Data Sources: A systematic search was performed to identify relevant studies, using the databases PubMed and Cochrane Central Register of Controlled Trials, without publication time restrictions. Study Eligibility Criteria: Randomized controlled trials comparing treatment with low-molecular-weight heparin or unfractionated heparin (with or without low-dose aspirin), in high-risk women, defined as either history of preeclampsia, intrauterine growth restriction, fetal demise, or miscarriage or being at high risk after first-trimester screening of preeclampsia. Study Appraisal and Synthesis Methods: The systematic review was conducted according to the Cochrane Handbook guidelines. The primary outcome was the development of preeclampsia. We performed prespecified subgroup analyses according to combination with low-dose aspirin, low-molecular-weight heparin type, gestational age when treatment was started, and study population (patients with thrombophilia, at high risk of preeclampsia or miscarriage). Secondary outcomes included small for gestational age, perinatal death, miscarriage, and placental abruption. Pooled odds ratios with 95% confidence intervals were calculated using a random-effects model. Quality of evidence was assessed using the grading of recommendations assessment, development, and evaluation methodology. Results: A total of 15 studies (2795 participants) were included. In high-risk women, treatment with low-molecular-weight heparin was associated with a reduction in the development of preeclampsia (odds ratio, 0.62; 95% confidence interval, 0.43-0.90; P=.010); small for gestational age (odds ratio, 0.61; 95% confidence interval, 0.44-0.85; P=.003), and perinatal death (odds ratio, 0.49; 95% confidence interval, 0.25-0.94; P=.030). This reduction was stronger if low-molecular-weight heparin was started before 16 weeks' gestation (13 studies, 2474 participants) for preeclampsia (odds ratio, 0.55; 95% confidence interval, 0.39-0.76; P=.0004). When only studies including low-dose aspirin as an intervention were analyzed (6 randomized controlled trials, 920 participants), a significant reduction was observed in those with combined treatment (low-molecular-weight heparin plus low-dose aspirin) compared with low-dose aspirin alone (odds ratio, 0.62; 95% confidence interval, 0.41-0.95; P=.030). Overall, adverse events were neither serious nor significantly different. Quality of evidence ranged from very low to moderate, mostly because of the lack of blinding, imprecision, and inconsistency. Conclusion: Low-molecular-weight heparin use was associated with a significant reduction in the risk of preeclampsia and other placenta-mediated complications in high-risk women and when treatment was started before 16 weeks' gestation. Combined treatment with low-dose aspirin was associated with a significant reduction in the risk of preeclampsia compared with low-dose aspirin alone. However, there exists important clinical and statistical heterogeneity, and therefore, these results merit confirmation in large well-designed clinical trials.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cardiovascular risk assessment in women at high risk for pre-eclampsia in first half of pregnancy

  • Ullmo, Johana|||0000-0002-9313-917X
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Bos-Real, L.|||0000-0002-6159-0644
  • Padilla-Lopez, Mireia|||0000-0002-4374-3870
  • Coma-Barbarà, Marina
  • Martorell, Silvia
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Llurba, Elisa|||0000-0003-4048-6407
Background: Women diagnosed with pre-eclampsia (PE), especially those with early-onset and severe forms, are at heightened risk of future cardiovascular disease (CVD). It is uncertain if women at high-risk for PE present cardiovascular impairment at the beginning of pregnancy. The aim of this study was to assess cardiovascular biomarkers and cardiac function in the first half of pregnancy in women at high-risk for PE. Methods: This was a prospective cohort study including women attending first trimester screening for PE. Risk of PE in the first trimester was calculated using a previously validated model, which includes maternal factors and biophysical markers. A cut-off of 1 in 250 was used to classify high-risk for developing PE. Maternal echocardiographic function and morphometry were evaluated, and peripheral blood samples were obtained to assess hematological and biochemical variables, including lipid profile and cardiovascular and angiogenic factors. Results: A total of 349 pregnant individuals were included; 257 at high-risk and 92 at low-risk for PE. Maternal echocardiography was performed at a mean ± SD gestational age of 14.9 ± 1.3 weeks and blood sampling at 16.3 ± 1.9 weeks. The high-risk PE group exhibited a significantly worse lipid profile (lower levels of high-density lipoproteins 69.7 ± 14.2 vs 74.0 ± 14.6 mg/dL, p=0.020), lower placental growth factor (0.89 ± 0.63 vs 1.15 ± 0.58 MoM, p<0.001), and significantly lower levels of N-terminal pro-brain natriuretic peptide (51.0 ± 2.1 vs 52.1 ± 2.0 ng/L, p=0.008). Echocardiographic evaluation indicated concentric remodeling, along with an altered diastolic pattern in the high-risk group. Conclusions: Women at high risk of developing PE exhibit differences in lipid profile, angiogenic factors, and echocardiographic parameters, indicative of cardiac maladaptation or impairment during the first half of pregnancy. These findings suggest a link between subclinical cardiovascular dysfunction, PE development and later CVD risk.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mapping of Determinants of Urinary Sex Steroid Metabolites During Late Pregnancy, Results from Two Spanish Cohorts

  • Laveriano-Santos, E.P.|||0000-0002-4852-6074
  • Renard Dausset, Estelle|||0009-0008-1258-090X
  • Bustamante, Mariona|||0000-0003-0127-2860
  • Pelegrí-Sisó, Dolors|||0000-0002-5993-3003
  • García Ruiz, Zoraida|||0009-0009-4631-763X
  • Ruiz-Rivera, Marina|||0009-0004-4537-8944
  • Cosin-Tomas, Marta|||0000-0001-5012-8983
  • Llurba, Elisa|||0000-0003-4048-6407
  • Gómez-Roig, María Dolores|||0000-0003-2329-1851
  • Haro, Noemí
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • Dadvand, Payam|||0000-0002-2325-1027
  • Vrijheid, Martine|||0000-0002-7090-1758
  • Maitre, Léa|||0000-0003-3682-7117
Steroid hormones (SHs), including sex steroids and corticosteroids, are crucial for a healthy pregnancy. We aimed to comprehensively characterize the maternal SH metabolome in late pregnancy and identify clinical, lifestyle, and sociodemographic determinants influencing SH metabolism with a replication in an independent cohort. Urinary SH metabolites were analyzed in 1221 third-trimester pregnant women (aged 28 to 37 years) from two Spanish cohorts, BiSC (2018-2021, n = 721) and INMA-Sabadell (2004-2006, n = 500), using targeted UHPLC-MS/MS. We quantified 50 SH metabolites, resulting in 13 hormone groups, 9 sulfate/glucuronide ratios, and 17 estimated steroid enzymatic activities across steroidogenesis pathways. We applied elastic net regression to identify determinants, and multivariable linear regression models to estimate variance explained. Among the 47 and 28 determinants from BiSC and INMA-Sabadell, respectively, 10 determinant-SH metabolome pairs showed statistically significant associations (p < 0.05), supporting robust replication. Maternal BMI was the main determinant linked to higher corticosteroid and androgen metabolites. Higher physical activity was associated with lower glucocorticoids and progestogen metabolites, while older maternal age was related with lower levels of androgen and corticosteroid metabolites. Tobacco exposure in the first trimester predicted higher levels of cortisol metabolites. Latin American women had lower cortolone levels compared with Spanish women. Parity, dietary fat intake, sleep, alcohol intake, and sex of the fetus contributed to smaller variations in different SHs. This dual-cohort analysis provides the most detailed and replicated evidence to date of how clinical, lifestyle, and sociodemographic factors shape the maternal SH metabolome during late pregnancy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Air pollution and fetal brain morphological development, a prospective cohort study

  • Eixarch, Elisenda|||0000-0001-7379-9608
  • Domínguez Gallardo, Carla|||0000-0002-5365-1005
  • Cirach, Marta
  • Nieuwenhuijsen, Mark|||0000-0001-9461-7981
  • Basagaña, X.|||0000-0002-8457-1489
  • Querol, Xavier
  • Foraster, Maria|||0000-0003-4450-4123
  • Bustamante, Mariona|||0000-0003-0127-2860
  • Pujol Nuez, Jesús|||0000-0002-9946-4547
  • Gascon, Mireia|||0000-0003-4537-8472
  • Llurba, Elisa|||0000-0003-4048-6407
  • Gómez-Roig, María Dolores|||0000-0003-2329-1851
  • Dadvand, Payam|||0000-0002-2325-1027
  • Sunyer, Jordi
  • Gómez Herrera, Laura|||0000-0002-5929-8409
  • Zhao, Yu
  • Rivas Lara, Ioar|||0000-0002-4743-619X
  • Galmes, Toni
  • Muniesa, Marta
  • Zanini, Julia|||0000-0002-6006-7595
  • Domínguez, Alan
Background: There is a scarcity of evidence of the influence of exposure to air pollution during pregnancy on the human fetal brain characterised prenatally. We aimed to evaluate the association of exposure to air pollution with fetal brain morphology. Methods: In this prospective cohort study, we used data from the Barcelona Life Study Cohort, Spain, which recruited 1080 pregnant women at 8-14 weeks of gestation between Oct 16, 2018, and April 14, 2021, from three major university hospitals in Barcelona. Eligible participants were aged 18-45 years, had a singleton pregnancy, and had a fetus without major congenital anomalies. Third-trimester transvaginal neurosonography was applied to evaluate fetal brain morphological development. We integrated comprehensive data on time-activity patterns with land use regression, dispersion, and hybrid models to estimate exposure to NO, PM, and black carbon at home, workplace, and commuting routes during pregnancy until the neurosonography date. Single-pollutant linear mixed regression models and multipollutant ridge regression models were applied to estimate the associations between air pollutants and fetal brain outcomes, controlled for confounders. Distributed lag linear models were used to identify the vulnerable windows. Findings: Among 1080 participants recruited at baseline, 954 attended the follow-up for the neurosonographic examination, 754 of whom were included in this study. In single-pollutant models, we found that prenatal exposure to NO, PM, and black carbon was associated with a wider anterior horn of lateral ventricles, wider cisterna magna, and larger cerebellar vermis. We also observed that higher exposure to black carbon was related to a shallower Sylvian fissure. No clear pattern or associations were observed between air pollution and other structures of brain morphology. Multipollutant models showed that these associations with black carbon remained significant, whereas associations with PM and NO lost significance for some indicators. A potential vulnerability window in mid-to-late pregnancy was identified for these associations. Interpretation: Exposure to air pollution might affect brain morphological development as early as the fetal stage. Our findings could have important policy implications as they highlight the need to mitigate exposure of pregnant individuals to air pollution in urban areas to protect fetal brain development. Funding: European Research Council.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association of in utero exposure to phthalate and DINCH metabolites with placental DNA methylation

  • Vespalcova, Hana|||0000-0003-0404-3166
  • Knox, B.|||0000-0001-5870-9344
  • Sakhi, Amrit K.|||0000-0002-2918-323X
  • Thomsen, C.|||0000-0002-6889-7868
  • Cosin-Tomas, Marta|||0000-0001-5012-8983
  • Gómez Herrera, Laura|||0000-0002-5929-8409
  • Sánchez García, Olga|||0000-0002-5279-440X
  • Llurba, Elisa|||0000-0003-4048-6407
  • Gómez-Roig, María Dolores|||0000-0003-2329-1851
  • Sunyer Deu, Jordi|||0000-0002-2602-4110
  • Dadvand, Payam|||0000-0002-2325-1027
  • Bustamante, Mariona|||0000-0003-0127-2860
  • Vrijheid, Martine|||0000-0002-7090-1758
  • Aguilar-Lacasaña, S.|||0000-0002-7953-1589
Phthalates and DINCH are non-persistent chemicals widely used in consumer products. In utero exposure to these compounds has been linked to adverse reproductive and long-term health outcomes, potentially through epigenetic changes in the placenta. This study investigated associations between maternal phthalate and DINCH metabolite levels and placental DNA methylation in 469 mother-child pairs from the Barcelona Life Study Cohort (BiSC). Fifteen phthalate and two DINCH metabolites were measured in pooled maternal urine samples collected at 19 and 35 weeks of gestation using liquid chromatography-tandem mass spectrometry (LC-MS/MS. Placental DNA methylation was assessed using the Illumina EPIC array. We applied robust linear regression models to test associations between single exposures at 19 weeks, 35 weeks, and whole pregnancy (average of the two time points), with each CpG site. In secondary analyses, quantile g-computation was used to test associations between exposure mixtures and suggestive CpGs (p-value < 1E-05). We identified 38 Bonferroni significant associations in the single exposure models (p-value < 1E-07)- 24 at 19 weeks, 8 at 35 weeks and 6 for the whole pregnancy period. Suggestive CpGs (p-value < 1E-05) were annotated to genes involved in metabolic, immune and vascular pathways, steroid biosynthesis, and sex hormone signaling. Sex-stratified analyses revealed 49 female-specific and 42 male-specific associations, most of which were identified at a single time point. Mixture analyses revealed 20 significant associations, all consistent in direction with the single-metabolite models. These results suggest that prenatal exposure to phthalates and DINCH may contribute to placental epigenetic alterations supporting a role for endocrine disruption, metabolism, and vascular and immune modulation in mediating their effects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dietary patterns and exposure to non-persistent endocrine-disrupting chemicals during pregnancy

  • Warkentin, Sarah|||0000-0002-6678-5256
  • Márquez, Sandra
  • Gascon, Mireia|||0000-0003-4537-8472
  • Güil-Oumrait, Nuria|||0000-0003-4097-7038
  • González-Palacios, Sandra|||0000-0003-3358-472X
  • Lassale, Camille|||0000-0002-9340-2708
  • Llurba, Elisa|||0000-0003-4048-6407
  • Rolland, Matthieu|||0000-0002-8076-5550
  • Sakhi, Amrit K.|||0000-0002-2918-323X
  • Thomsen, C.|||0000-0002-6889-7868
  • Vioque, Jesús|||0000-0002-2284-148X
  • Bustamante, Mariona|||0000-0003-0127-2860
  • Sunyer Deu, Jordi|||0000-0002-2602-4110
  • Vrijheid, Martine|||0000-0002-7090-1758
  • Vespalcova, Hana|||0000-0003-0404-3166
  • Knox, Bethany
  • Gómez-Roig, María Dolores|||0000-0003-2329-1851
Background: Exposure to non-persistent endocrine disrupting chemicals (EDCs) is widespread, causing various adverse health effects, especially during pregnancy. Diet is a major source of EDCs and the identification of dietary patterns that give rise to higher exposure levels is crucial. We aimed to explore the relationship between dietary patterns during pregnancy and exposure to non-persistent EDCs. Methods: We included 640 pregnant women from the Barcelona Life Study Cohort (BiSC), Spain. Using food frequency questionnaires (2nd trimester), we estimated ultraprocessed food (UPF) consumption and Mediterranean diet adherence, and derived data-driven dietary patterns. Metabolites of phthalates, 1,2-cyclohexane dicarboxylic acid di(isononyl) ester (DINCH), chlorpyrifos and pyrethroid, polycyclic aromatic hydrocarbons (PAHs, including phenanthrenes), and organophosphates, and parent compounds of phenols and parabens were measured in weekly urine pools (3rd trimester). Associations between dietary patterns and EDCs were evaluated through multivariable linear regressions. Results: Higher compliance with a "Vegetarian" pattern or the Mediterranean diet was associated with lower levels of some of the phthalate metabolites (e.g., di-iso-nonyl phthalates [Geometric mean ratio (GMR) per unit increases in the "Vegetarian" score = 0.97, 95 %CI 0.95, 1.00]). Conversely, "Western" and "Animal protein" patterns, and UPF intake were associated with higher PAHs (e.g., "Western" and 2-Hydroxynaphthalene [GMR(95 %CI) 1.07(1.01, 1.13)]), pesticides (e.g., "Animal protein" and 3-Phenoxybenzoic acid [1.15(1.01, 1.32]), and phthalates metabolites levels (e.g., UPF and Monoethyl phthalate [1.05(1.01, 1.09)]). No association remained significant after correcting for multiple testing. Conclusions: Following a plant-based diet may help reduce the exposure to certain phthalate and organophosphate metabolites, whereas higher consumption of foods from animal origin and high in fat/sugar/salt may increase exposure to PAHs, pesticides, and phthalates metabolites in pregnancy.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prenatal phenol exposure and child behaviour, insights into the hypothalamic-pituitary-adrenal axis from two prospective mother-child cohorts

  • Rolland, Matthieu|||0000-0002-8076-5550
  • Bustamante, Mariona|||0000-0003-0127-2860
  • Jedynak, Paulina|||0000-0002-9525-8308
  • Thomsen, Cathrine
  • Sakhi, Amrit K.|||0000-0002-2918-323X
  • Foraster, Maria|||0000-0003-4450-4123
  • Gascon, Mireia|||0000-0003-4537-8472
  • Llurba, Elisa|||0000-0003-4048-6407
  • Rivas Lara, Ioar|||0000-0002-4743-619X
  • Ferrer, Muriel
  • Bayat, Sam|||0000-0002-8565-0293
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • Vrijheid, Martine|||0000-0002-7090-1758
  • Sunyer, Jordi
  • Slama, Rémy
  • Dadvand, Payam|||0000-0002-2325-1027
  • Gómez-Roig, María Dolores|||0000-0003-2329-1851
  • Ouellet-Morin, Isabelle
  • Morillas, Alex
  • Carras, Sylvain
  • Lyon-Caen, Sarah
  • Philippat, Claire
Background: Synthetic phenols are widely used chemicals with potential neurodevelopmental toxicity. Human studies are often limited by small sample sizes and exposure misclassification. Identifying the biological pathways affected by these substances is crucial for understanding key drivers of toxicity. We aimed to study associations between prenatal exposure to synthetic phenols and child behaviour, exploring the potential mediating role of maternal steroid hormones.MethodsWe pooled data from two European cohorts: the Barcelona Life Study Cohort (BiSC; Barcelona, Spain, 2018-21, N=1080) and Suivi de l'Exposition à la Pollution Atmosphérique durant la Grossesse et Effets sur la Santé (SEPAGES; Grenoble, France, 2014-17, N=484). Mothers older than 18 years having a singleton pregnancy of less than 19 weeks gestational age were eligible for inclusion in the cohorts; those having multiple pregnancies were excluded. Repeated urine samples (up to 24 in BiSC; up to 42 in SEPAGES) collected in the second and third trimesters were pooled and analysed for 12 synthetic phenols. Child behavioural outcomes were assessed at 18 months in BiSC and 24 months in SEPAGES using the Child Behavior Checklist for Ages 1·5-5 (CBCL). Concentrations of total cortisol, total cortisone, and 11-dehydrocorticosterone-steroid hormones involved in the hypothalamic-pituitary-adrenal axis-were measured from maternal hair samples. Associations between phenol exposure and behavioural outcomes were estimated by adjusted linear regression analysis, and mediation by steroid hormones was assessed with regression-based causal mediation analysis within the counterfactual framework.Findings1024 mother-child pairs were included in the study: 607 from BiSC and 417 from SEPAGES. Maternal exposure to methylparaben in the third trimester of pregnancy was associated with higher internalising scores (change in score of 0·44 [95% CI 0·10-0·79] points) and externalising scores (0·67 [0·12-1·24]) in the CBCL. In boys, maternal exposure to bisphenol S in the third trimester was linked to increased internalising scores (0·92 [0·15 to 1·75]; p=0·019) and could be linked to increased externalising scores (1·14 [−0·09 to 2·44]; p=0·070). In girls, second-trimester butylparaben and propylparaben exposure were associated with lower internalising (−1·03 [−1·84 to −0·09], p=0·033) and externalising (−0·68 [−1·23 to −0·12]; p=0·019) scores. No mediation by steroid hormones was observed.InterpretationPrenatal exposure to phenols might influence early behavioural development, with sex-specific patterns. There was no strong evidence of mediation by maternal steroid hormones, suggesting the involvement of alternative pathways in the biological effects of phenols. Together with previous findings, these results highlight the need for stricter regulation of these compounds to reduce prenatal exposure.FundingFrench Agency for Food, Environmental and Occupational Health & Safety, the EU's Horizon 2020 research and innovation programme, and the French Fund - Fondation de France.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

N-terminal pro B-type natriuretic peptide as biomarker to predict pre-eclampsia and maternal-fetal complications

  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Universitat Autònoma de Barcelona.
  • Garrido-Giménez, Carmen|||0000-0003-2180-1715
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Platero, Judit|||0000-0001-6007-9855
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Llurba, Elisa|||0000-0003-4048-6407
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • García Manau, Pablo|||0000-0002-2415-1626
  • Ullmo, Johana|||0000-0002-9313-917X
  • Sánchez García, Olga|||0000-0002-5279-440X
  • Vila-Cortés, M.
  • Pelegay, M. J.
  • Ricart, M
  • Muñoz-Abellana, B.
  • Barrios, X. Gabaldó
Objective: A soluble fms-like tyrosine kinase-1 (sFlt-1)-to-placental growth factor (PlGF) ratio cut-off of 38 is currently considered optimal for ruling out pre-eclampsia (PE); however, implementation of this ratio in clinical practice is limited. N-terminal pro B-type natriuretic peptide (NT-proBNP) is elevated in PE owing to the cardiovascular effects of this disease. This study aimed to identify the predictive performance of NT-proBNP to detect PE and placental complications within 1 week after assessment, and compare it with the predictive performance of the sFlt-1/PlGF ratio. High-sensitivity troponin T (hs-TnT) and uric acid were also evaluated. Methods: This was a prospective nested case-control study conducted in five Spanish centers between March 2018 and December 2020, and comprised women with a singleton pregnancy and suspected PE between 24 + 0 and 41 + 0 weeks' gestation. We evaluated the ability of the sFlt-1/PlGF ratio, NT-proBNP, hs-TnT and uric acid to predict the development of any-onset (at any gestational age), early-onset (before 34 weeks) or term (at or after 37 weeks) PE within 1 week or 4 weeks after assessment. Predictive performance was assessed by estimating negative predictive values, positive predictive values, sensitivity, specificity and areas under the receiver-operating-characteristics curves (AUCs) for these biomarkers, with corresponding 95% CIs. We performed post-hoc exploratory analyses of associations between the sFlt-1/PlGF ratio, NT-proBNP, hs-TnT and uric acid in women who developed PE, as well as in women who developed complicated PE (PE plus fetal growth restriction, stillbirth or placental abruption) within 1 week and 4 weeks after assessment. Results: A total of 323 women with suspected PE at or before 41 + 0 weeks were enrolled in the study, of whom seven were lost to follow-up. The final analysis included 316 eligible participants, with 424 samples. The overall incidence of PE was 23.4% (n = 74) and early-onset PE developed in 8.5% (n = 27) of cases. The sFlt-1/PlGF ratio and NT-proBNP exhibited similar abilities to predict early-onset PE within 1 week after assessment (AUC, 0.970 (95% CI, 0.932-1.000) and 0.971 (95% CI, 0.942-1.000), respectively). hs-TnT and uric acid demonstrated inferior predictive capability compared with the sFlt-1/PlGF ratio for the prediction of any-onset PE, early-onset PE and term PE within 1 week and 4 weeks after assessment. The optimal cut-off for NT-proBNP was 116 pg/mL. At this cut-off, NT-proBNP showed a sensitivity of 90.9% (95% CI, 70.8-98.9%) and a specificity of 94.3% (95% CI, 91.2-96.5%), with a positive predictive value of 5.7% (95% CI, 3.7-8.7%) and a negative predictive value of 99.9% (95% CI, 99.9-100%) in predicting early-onset PE within 1 week of assessment, which was comparable with that of the sFlt-1/PlGF ratio. Participants with PE-related complications had higher levels of all biomarkers, but only NT-proBNP showed a similar predictive ability to the sFlt-1/PlGF ratio for complicated PE within 1 week after assessment (AUC, 0.818 (95% CI, 0.706-0.930) vs 0.822 (95% CI, 0.723-0.921), respectively). Conclusion: An NT-proBNP cut-off value of 116 pg/mL has a similar diagnostic performance to that of the sFlt-1/PlGF ratio in predicting the diagnosis of early-onset PE within 1 week after assessment. Thus, NT-proBNP could be used in clinical practice for the early identification and management of PE, particularly in cases for which the sFlt-1/PlGF ratio is not available. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The evolving microbiome from pregnancy to early infancy: A comprehensive review

  • Mesa, María D.
  • Loureiro, Begoña
  • Iglesia, Iris
  • Fernandez Gonzalez, Sergi
  • Llurba Olivé, Elisa
  • García Algar, Oscar
  • Solana, María J.
  • Cabero Perez, Mª J.
  • Sainz, Talia
  • Martinez, Leopoldo
  • Escuder-Vieco, Diana
  • Parra-Llorca, Anna
  • Sánchez-Campillo, María
  • Rodriguez Martinez, Gerardo
  • Gómez Roig, Dolores
  • Perez Gruz, Myriam
  • Andreu-Fernández, Vicente
  • Clotet, Jordi
  • Sailer, Sebastian
  • Iglesias-Platas, Isabel
  • López-Herce, Jesús
  • Aras, Rosa
  • Pallás-Alonso, Carmen
  • de Pipaon, Miguel S.
  • Vento, Máximo
  • Gormaz, María
  • Larqué Daza, Elvira
  • Calvo, Cristina
  • Cabañas, Fernando
Pregnancy induces a number of immunological, hormonal, and metabolic changes that are necessary for the mother to adapt her body to this new physiological situation. The microbiome of the mother, the placenta and the fetus influence the fetus growth and undoubtedly plays a major role in the adequate development of the newborn infant. Hence, the microbiome modulates the inflammatory mechanisms related to physiological and pathological processes that are involved in the perinatal progress through different mechanisms. The present review summarizes the actual knowledge related to physiological changes in the microbiota occurring in the mother, the fetus, and the child, both during neonatal period and beyond. In addition, we approach some specific pathological situations during the perinatal periods, as well as the influence of the type of delivery and feeding.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy

  • Sanchez García, Olga
  • Martínez, Sandra
  • Dominguez Luengo, Mari Carmen
  • Ruiz Pace, Fiorella
  • Céspedes Domínguez, María Concepción
  • Peñuelas Saiz, Angeles
  • Cortés Castan, Javier
  • Saura Manich, Cristina
  • Dienstmann, Rodrigo
Factors angiogènics; Quimioteràpia; Embaràs, Factores angiogénicos; Quimioterapia; Embarazo, Angiogenic factors; Chemotherapy; Pregnancy, High prevalence of placental-derived complications, such as preeclampsia and intrauterine growth restriction, has been reported in women with breast cancer (BC) treated with chemotherapy during pregnancy (PBC-CHT). Aim: To ascertain whether PBC-CHT is associated with an imbalance of angiogenic factors, surrogate markers for placental insufficiency, that could explain perinatal outcomes. Methods: Prospective study between 2012 and 2016 in a single institution. Soluble fms-like tyrosine kinase (sFlt-1), placental growth factor (PlGF), and soluble endoglin (sEng) in maternal blood were assessed throughout pregnancy in 12 women with BC and 215 controls. Results: Cancer patients were treated with doxorubicin-based regimes and with taxanes. Ten PBC-CHT (83%) developed obstetrical complications. At the end of the third trimester, significantly higher levels of sFlt-1; sFlt-1/PGF ratio, and sEng levels were observed in BC women as compared to controls. Moreover; there was a significant correlation between plasma levels of sFlt-1 and the number of chemotherapy cycles administered. Besides, more chemotherapy cycles correlated with lower birthweight and head circumference at birth. Conclusions: Women with BC treated during pregnancy showed an antiangiogenic state compatible with placental insufficiency. Angiogenic factors could be useful in the clinical obstetric management of these patients; although further studies will be required to guide clinical decision-making., This study was funded by the Spanish Research Project in Health funded by ISCIII, the state plan for scientific and technical research and innovation 2015–2018, and European Regional Development Fund (ERDF), ref. PI15/02252. This study was also supported in part by RETICS ‘Maternal and Child Health and Development Network’ (SAMID Network), funded by the PN I + D + i 2008–2016 (Spain), ISCIII-Sub-Directorate General for Research Assessment and Promotion, and the European Regional Development Fund (ERDF), ref. RD12/0026 and RD16/0022. O.S. was supported by SAMID Network (RD12/0026/0016 and RD16/0022/0015) and S.M. was supported by “Paseico de la mama”.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Predictive Model for Preeclampsia Combining sFlt-1, PlGF, NT-proBNP, and Uric Acid as Biomarkers

  • Cruz-Lemini, Mónica
  • Álvarez, Francisco V.
  • Nan, Madalina Nicoleta
  • Carretero, Francisco
  • Fernández-Oliva, Antonio
  • Alijotas Reig, Jaume
  • Garrido-Giménez, Carmen
Angiogenic factors; Preeclampsia; Uric acid, Factores angiogénicos; Preeclampsia; Ácido úrico, Factors angiogènics; Preeclàmpsia; Àcid úric, N-terminal pro-brain natriuretic peptide (NT-proBNP) and uric acid are elevated in pregnancies with preeclampsia (PE). Short-term prediction of PE using angiogenic factors has many false-positive results. Our objective was to validate a machine-learning model (MLM) to predict PE in patients with clinical suspicion, and evaluate if the model performed better than the sFlt-1/PlGF ratio alone. A multicentric cohort study of pregnancies with suspected PE between 24+0 and 36+6 weeks was used. The MLM included six predictors: gestational age, chronic hypertension, sFlt-1, PlGF, NT-proBNP, and uric acid. A total of 936 serum samples from 597 women were included. The PPV of the MLM for PE following 6 weeks was 83.1% (95% CI 78.5-88.2) compared to 72.8% (95% CI 67.4-78.4) for the sFlt-1/PlGF ratio. The specificity of the model was better; 94.9% vs. 91%, respectively. The AUC was significantly improved compared to the ratio alone [0.941 (95% CI 0.926-0.956) vs. 0.901 (95% CI 0.880-0.921), p < 0.05]. For prediction of preterm PE within 1 week, the AUC of the MLM was 0.954 (95% CI 0.937-0.968); significantly greater than the ratio alone [0.914 (95% CI 0.890-0.934), p < 0.01]. To conclude, an MLM combining the sFlt-1/PlGF ratio, NT-proBNP, and uric acid performs better to predict preterm PE compared to the sFlt-1/PlGF ratio alone, potentially increasing clinical precision., This work was supported by public funds obtained in competitive calls with peer review (grant PI19/00702), Insituto de Salud Carlos III, Spanish Ministry of Health, by the Maternal and Child Health and Development Network (SAMID, RD16/0022/0015), Instituto de Salud Carlos III, Madrid, Spain, the Spanish Clinical Research and Clinical Trials Platform, SCReN (Spanish Clinical Research Network), funded by the ISCIII-General Subdirectorate for Evaluation and Promotion of Research, through project PT13/0002/0028, integrated in the 2013–2016 R + D + I State Plan and co-financed by and the European Regional Development Fund (FEDER); and by the Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin Network (RICORS, RD21/0012/0001), Instituto de Salud Carlos III, Madrid, Spain, funded by the Recovery, Transformation and Resilience Plan 2017–2020, ISCIII, and by the European Union-Next Generation EU. Dr Cruz-Lemini is supported by Juan Rodés contract JR19/00047, Instituto de Salud Carlos III-Spanish Ministry of Health. Funding sources were not involved in study design, collection, analysis, and interpretation of data.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The Evolving Microbiome from Pregnancy to Early Infancy, A Comprehensive Review

  • Mesa, María Dolores|||0000-0003-4079-6464
  • Loureiro, Begoña|||0000-0001-6065-1364
  • Iglesia, Iris|||0000-0002-2219-3646
  • Fernandez Gonzalez, Sergi
  • Llurba, Elisa|||0000-0003-4048-6407
  • Garcia-Algar, Oscar|||0000-0001-5708-4362
  • Solana, María José|||0000-0001-6083-2528
  • Cabero Perez, Mª Jesús
  • Sainz, Talia|||0000-0002-5301-0945
  • Martinez, Leopoldo
  • Escuder-Vieco, Diana
  • Parra-Llorca, Anna
  • Sánchez-Campillo, María|||0000-0002-7177-8341
  • Rodriguez Martinez, Gerardo
  • Gómez-Roig, María Dolores|||0000-0003-2329-1851
  • Perez Gruz, Myriam
  • Andreu-Fernandez, Vicente|||0000-0001-7183-8706
  • Clotet, Jordi
  • Sailer, Sebastian
  • Iglesias-Platas, Isabel
  • López Herce, Jesús|||0000-0001-6105-9178
  • Aras, Rosa
  • Pallás-Alonso, Carmen|||0000-0001-9710-8162
  • Saenz de Pipaon, Miguel|||0000-0002-4793-1561
  • Vento Torres, Máximo|||0000-0003-0061-4742
  • Gormaz, María
  • Larqué Daza, Elvira
  • Calvo, Cristina|||0000-0002-6503-3423
  • Cabañas, Fernando
Pregnancy induces a number of immunological, hormonal, and metabolic changes that are necessary for the mother to adapt her body to this new physiological situation. The microbiome of the mother, the placenta and the fetus influence the fetus growth and undoubtedly plays a major role in the adequate development of the newborn infant. Hence, the microbiome modulates the inflammatory mechanisms related to physiological and pathological processes that are involved in the perinatal progress through different mechanisms. The present review summarizes the actual knowledge related to physiological changes in the microbiota occurring in the mother, the fetus, and the child, both during neonatal period and beyond. In addition, we approach some specific pathological situations during the perinatal periods, as well as the influence of the type of delivery and feeding. his research was funded by the PN I+D+I 2008-2011 (Spain), ISCIII- Sub-Directorate General for Research Assessment and Promotion and the European Regional Development Fund (ERDF), RETICS Maternal and Child Health and Development Network, SAMID Network, Ref.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy

  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Sánchez Martínez, M. Olga|||0000-0003-1254-012X
  • Martínez, Sandra
  • Domínguez Luengo, Carmen|||0000-0003-4684-1887
  • Dienstmann, Rodrigo|||0000-0001-5997-318X
  • Ruíz-Pace, Fiorella|||0000-0002-3932-0170
  • Céspedes, Maria Concepció
  • Peñuelas, Ángeles
  • Cortés Castán, Javier|||0000-0001-7623-1583
  • Llurba, Elisa|||0000-0003-4048-6407
  • Cordoba Cardona, Octavi|||0000-0002-9591-7430
Anthracyclines and taxanes are being used as a standard treatment for breast cancer diagnosed during pregnancy. These chemotherapy regimens allow the continuation of pregnancy without delaying cancer treatment with relatively good maternal and neonatal outcomes. However, their effects on placental function and fetal development are not completely understood. Maternal serum angiogenic factors are a surrogate of placental function and are abnormal weeks before placental complications such as preeclampsia or intrauterine growth restriction development. In our cohort, pregnant women with breast cancer treated with chemotherapy during pregnancy show an antiangiogenic state with significantly higher levels of soluble fms-like tyrosine kinase (sFlt-1), sFlt-1/PGF ratio, and soluble endoglin (sEng) at the end of the third trimester. Angiogenic factors could be useful in the clinical obstetric management of these patients, although more studies are guaranteed. High prevalence of placental-derived complications, such as preeclampsia and intrauterine growth restriction, has been reported in women with breast cancer (BC) treated with chemotherapy during pregnancy (PBC-CHT). Aim: To ascertain whether PBC-CHT is associated with an imbalance of angiogenic factors, surrogate markers for placental insufficiency, that could explain perinatal outcomes. Methods: Prospective study between 2012 and 2016 in a single institution. Soluble fms-like tyrosine kinase (sFlt-1), placental growth factor (PlGF), and soluble endoglin (sEng) in maternal blood were assessed throughout pregnancy in 12 women with BC and 215 controls. Results: Cancer patients were treated with doxorubicin-based regimes and with taxanes. Ten PBC-CHT (83%) developed obstetrical complications. At the end of the third trimester, significantly higher levels of sFlt-1; sFlt-1/PGF ratio, and sEng levels were observed in BC women as compared to controls. Moreover; there was a significant correlation between plasma levels of sFlt-1 and the number of chemotherapy cycles administered. Besides, more chemotherapy cycles correlated with lower birthweight and head circumference at birth. Conclusions: Women with BC treated during pregnancy showed an antiangiogenic state compatible with placental insufficiency. Angiogenic factors could be useful in the clinical obstetric management of these patients; although further studies will be required to guide clinical decision-making.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cardiac dysfunction and remodeling regulated by anti-angiogenic environment in patients with preeclampsia, the ANGIOCOR prospective cohort study protocol

  • Ullmo, Johana|||0000-0002-9313-917X
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Sánchez García, Olga|||0000-0002-5279-440X
  • Bos-Real, L.|||0000-0002-6159-0644
  • Fernandez-Llama, Patricia|||0000-0002-7472-2124
  • Calero, Francesca|||0000-0002-5758-0769
  • Domínguez Gallardo, Carla|||0000-0002-5365-1005
  • Garrido-Giménez, Carmen|||0000-0003-2180-1715
  • Trilla, Cristina|||0000-0002-5650-1790
  • Carreras Costa, Francesc|||0000-0002-1944-0562
  • Sionis, Alessandro|||0000-0003-0843-9512
  • Mora, J.
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Ordóñez, J. (Jordi)|||0000-0003-4896-5832
  • Llurba, Elisa|||0000-0003-4048-6407
Background: Cardiovascular diseases (CVD) are cause of increased morbidity and mortality in spite of advances for diagnosis and treatment. Changes during pregnancy affect importantly the maternal CV system. Pregnant women that develop preeclampsia (PE) have higher risk (up to 4 times) of clinical CVD in the short- and long-term. Predominance of an anti-angiogenic environment during pregnancy is known as main cause of PE, but its relationship with CV complications is still under research. We hypothesize that angiogenic factors are associated to maternal cardiac dysfunction/remodeling and that these may be detected by new cardiac biomarkers and maternal echocardiography. Methods: Prospective cohort study of pregnant women with high-risk of PE in first trimester screening, established diagnosis of PE during gestation, and healthy pregnant women (total intended sample size n = 440). Placental biochemical and biophysical cardiovascular markers will be assessed in the first and third trimesters of pregnancy, along with maternal echocardiographic parameters. Fetal cardiac function at third trimester of pregnancy will be also evaluated and correlated with maternal variables. Maternal cardiac function assessment will be determined 12 months after delivery, and correlation with CV and PE risk variables obtained during pregnancy will be evaluated. Discussion: The study will contribute to characterize the relationship between anti-angiogenic environment and maternal CV dysfunction/remodeling, during and after pregnancy, as well as its impact on future CVD risk in patients with PE. The ultimate goal is to improve CV health of women with high-risk or previous PE, and thus, reduce the burden of the disease. Trial registration: NCT04162236.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Predictive Model for Preeclampsia Combining sFlt-1, PlGF, NT-proBNP, and Uric Acid as Biomarkers

  • Garrido-Giménez, Carmen|||0000-0003-2180-1715
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Álvarez Menéndez, Francisco V.|||0000-0002-2553-5402
  • Nan, Madalina Nicoleta|||0009-0001-2794-447X
  • Carretero, Francisco
  • Fernández-Oliva, Antonio|||0000-0002-8610-2600
  • Mora Brugués, Josefina|||0000-0001-6777-5132
  • Sánchez García, Olga|||0000-0002-5279-440X
  • García Osuna, Álvaro|||0000-0002-6682-0226
  • Alijotas-Reig, Jaume|||0000-0002-9212-3619
  • Llurba, Elisa|||0000-0003-4048-6407
N-terminal pro-brain natriuretic peptide (NT-proBNP) and uric acid are elevated in pregnancies with preeclampsia (PE). Short-term prediction of PE using angiogenic factors has many false-positive results. Our objective was to validate a machine-learning model (MLM) to predict PE in patients with clinical suspicion, and evaluate if the model performed better than the sFlt-1/PlGF ratio alone. A multicentric cohort study of pregnancies with suspected PE between 24 +0 and 36 +6 weeks was used. The MLM included six predictors: gestational age, chronic hypertension, sFlt-1, PlGF, NT-proBNP, and uric acid. A total of 936 serum samples from 597 women were included. The PPV of the MLM for PE following 6 weeks was 83.1% (95% CI 78.5-88.2) compared to 72.8% (95% CI 67.4-78.4) for the sFlt-1/PlGF ratio. The specificity of the model was better; 94.9% vs. 91%, respectively. The AUC was significantly improved compared to the ratio alone [0.941 (95% CI 0.926-0.956) vs. 0.901 (95% CI 0.880-0.921), p < 0.05]. For prediction of preterm PE within 1 week, the AUC of the MLM was 0.954 (95% CI 0.937-0.968); significantly greater than the ratio alone [0.914 (95% CI 0.890-0.934), p < 0.01]. To conclude, an MLM combining the sFlt-1/PlGF ratio, NT-proBNP, and uric acid performs better to predict preterm PE compared to the sFlt-1/PlGF ratio alone, potentially increasing clinical precision.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Longitudinal Behavior of Left-Ventricular Strain in Fetal Growth Restriction

  • Domínguez Gallardo, Carla|||0000-0002-5365-1005
  • Ginjaume García, Nuria|||0000-0003-0785-0115
  • Ullmo, Johana|||0000-0002-9313-917X
  • Fernández-Oliva, Antonio|||0000-0002-8610-2600
  • Parra Roca, Juan|||0000-0001-6011-7815
  • Vázquez Fariñas, Ana|||0000-0001-6732-1667
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Llurba, Elisa|||0000-0003-4048-6407
Fetal growth restriction (FGR) is associated with an increased risk of adverse outcomes resulting from adaptive cardiovascular changes in conditions of placental insufficiency, leading to cardiac deformation and dysfunction, which can be evaluated with 2D speckle tracking echocardiography (2D-STE). The aim of the present study was to evaluate whether reduced fetal growth is associated with cardiac left-ventricle (LV) dysfunction, using 2D-STE software widely used in postnatal echocardiography. A prospective longitudinal cohort study was performed, and global (GLO) and segmental LV longitudinal strain was measured offline and compared between FGR and appropriate-for-gestational-age (AGA) fetuses throughout gestation. All cases of FGR fetuses were paired 1:2 to AGA fetuses, and linear mixed model analysis was performed to compare behavior differences between groups throughout pregnancy. Our study shows LV fetal longitudinal strain in FGR and AGA fetuses differed upon diagnosis and behaved differently throughout gestation. FGR fetuses had lower LV strain values, both global and segmental, in comparison to AGA, suggesting subclinical cardiac dysfunction. Our study provides more data regarding fetal cardiac function in cases of placental dysfunction, as well as highlights the potential use of 2D-STE in the follow-up of cardiac function in these fetuses.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cord Blood Cardiovascular Biomarkers in Left-Sided Congenital Heart Disease

  • Soveral, Iris|||0000-0002-3571-1780
  • Guirado, Laura
  • Escobar-Diaz, Maria C.|||0000-0001-9875-3593
  • Alcaide, María José|||0000-0003-3472-8107
  • Martínez Crespo, Josep Maria
  • Rodríguez Sureda, Víctor|||0000-0003-4942-9249
  • Bijnens, Bart
  • Antolin, Eugenia
  • Llurba, Elisa|||0000-0003-4048-6407
  • Bartha, José Luis
  • Gómez, Olga|||0000-0003-4183-9876
  • Crispi, Fatima|||0000-0002-7422-5240
Fetal echocardiography has limited prognostic ability in the evaluation of left-sided congenital heart defects (left heart defects). Cord blood cardiovascular biomarkers could improve the prognostic evaluation of left heart defects. A multicenter prospective cohort (2013-2019) including fetuses with left heart defects (aortic coarctation, aortic stenosis, hypoplastic left heart, and multilevel obstruction (complex left heart defects) subdivided according to their outcome (favorable vs. poor), and control fetuses were evaluated in the third trimester of pregnancy at three referral centers in Spain. Poor outcome was defined as univentricular palliation, heart transplant, or death. Cord blood concentrations of N-terminal precursor of B-type natriuretic peptide, Troponin I, transforming growth factor β, placental growth factor, and soluble fms-like tyrosine kinase-1 were determined. A total of 45 fetuses with left heart defects (29 favorable and 16 poor outcomes) and 35 normal fetuses were included, with a median follow-up of 3.1 years (interquartile range 1.4-3.9). Left heart defects with favorable outcome showed markedly increased cord blood transforming growth factor β (normal heart median 15.5 ng/mL (6.8-21.4) vs. favorable outcome 51.7 ng/mL (13.8-73.9) vs. poor outcome 25.1 ng/mL (6.9-39.0), p = 0.001) and decreased placental growth factor concentrations (normal heart 17.9 pg/mL (13.8-23.9) vs. favorable outcome 12.8 pg/mL (11.7-13.6) vs. poor outcome 11.0 pg/mL (8.8-15.4), p < 0.001). Poor outcome left heart defects had higher N-terminal precursor of B-type natriuretic peptide (normal heart 508.0 pg/mL (287.5-776.3) vs. favorable outcome 617.0 pg/mL (389.8-1087.8) vs. poor outcome 1450.0 pg/mL (919.0-1645.0), p = 0.001) and drastically reduced soluble fms-like tyrosine kinase-1 concentrations (normal heart 1929.7 pg/mL (1364.3-2715.8) vs. favorable outcome (1848.3 pg/mL (646.9-2313.6) vs. poor outcome 259.0 pg/mL (182.0-606.0), p < 0.001). Results showed that fetuses with left heart defects present a distinct cord blood biomarker profile according to their outcome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Fetal Left Ventricle Function Evaluated by Two-Dimensional Speckle-Tracking Echocardiography across Clinical Stages of Severity in Growth-Restricted Fetuses

  • Domínguez Gallardo, Carla|||0000-0002-5365-1005
  • Ginjaume García, Nuria|||0000-0003-0785-0115
  • Ullmo, Johana|||0000-0002-9313-917X
  • Parra Roca, Juan|||0000-0001-6011-7815
  • Vázquez Fariñas, Ana|||0000-0001-6732-1667
  • Cruz-Lemini, Monica|||0000-0002-6807-3578
  • Llurba, Elisa|||0000-0003-4048-6407
Fetal growth restriction (FGR) can result in adverse perinatal outcomes due to cardiac dysfunction. This study used 2D speckle-tracking echocardiography to assess left ventricle (LV) longitudinal strain across FGR severity stages. A prospective longitudinal cohort study measured global (GLS) and segmental LV longitudinal strain in FGR fetuses, with evaluations conducted at various time points. FGR was classified into subtypes based on published criteria using fetal weight centile and Doppler parameters. A linear mixed model was employed to analyze repeated measures and compare Z-score measurements between groups throughout gestational age. The study included 40 FGR fetuses and a total of 107 evaluations were performed: 21 from small for gestational age (SGA), 74 from the FGR stage I, and 12 from the FGR stage ≥ II. The results indicate that SGA and stage I FGR fetuses exhibit higher LV GLS than stages ≥ II. Throughout gestation, SGA and FGR stage I fetuses showed similar behavior with consistently better LV GLS values when compared to FGR stages ≥ II. No significant differences were observed in LV GLS strain behavior between SGA and FGR stage I. In conclusion, all FGRs show signs of early cardiac dysfunction, with severe cases demonstrating significantly a lower LV GLS when compared to mild cases, suggesting deterioration of cardiac dysfunction with progression of fetal compromise.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy

  • Sanchez García, Olga
  • Martínez, Sandra
  • Dominguez Luengo, Mari Carmen
  • Ruiz-Pace, Fiorella
  • Céspedes Domínguez, María Concepción
  • Peñuelas Saiz, Angeles
  • Cortés Castan, Javier
  • Saura Manich, Cristina
  • Dienstmann, Rodrigo
Factors angiogènics; Quimioteràpia; Embaràs, Factores angiogénicos; Quimioterapia; Embarazo, Angiogenic factors; Chemotherapy; Pregnancy, High prevalence of placental-derived complications, such as preeclampsia and intrauterine growth restriction, has been reported in women with breast cancer (BC) treated with chemotherapy during pregnancy (PBC-CHT). Aim: To ascertain whether PBC-CHT is associated with an imbalance of angiogenic factors, surrogate markers for placental insufficiency, that could explain perinatal outcomes. Methods: Prospective study between 2012 and 2016 in a single institution. Soluble fms-like tyrosine kinase (sFlt-1), placental growth factor (PlGF), and soluble endoglin (sEng) in maternal blood were assessed throughout pregnancy in 12 women with BC and 215 controls. Results: Cancer patients were treated with doxorubicin-based regimes and with taxanes. Ten PBC-CHT (83%) developed obstetrical complications. At the end of the third trimester, significantly higher levels of sFlt-1; sFlt-1/PGF ratio, and sEng levels were observed in BC women as compared to controls. Moreover; there was a significant correlation between plasma levels of sFlt-1 and the number of chemotherapy cycles administered. Besides, more chemotherapy cycles correlated with lower birthweight and head circumference at birth. Conclusions: Women with BC treated during pregnancy showed an antiangiogenic state compatible with placental insufficiency. Angiogenic factors could be useful in the clinical obstetric management of these patients; although further studies will be required to guide clinical decision-making., This study was funded by the Spanish Research Project in Health funded by ISCIII, the state plan for scientific and technical research and innovation 2015–2018, and European Regional Development Fund (ERDF), ref. PI15/02252. This study was also supported in part by RETICS ‘Maternal and Child Health and Development Network’ (SAMID Network), funded by the PN I + D + i 2008–2016 (Spain), ISCIII-Sub-Directorate General for Research Assessment and Promotion, and the European Regional Development Fund (ERDF), ref. RD12/0026 and RD16/0022. O.S. was supported by SAMID Network (RD12/0026/0016 and RD16/0022/0015) and S.M. was supported by “Paseico de la mama”.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Predictive Model for Preeclampsia Combining sFlt-1, PlGF, NT-proBNP, and Uric Acid as Biomarkers

  • Cruz-Lemini, Mónica
  • Álvarez, Francisco V.
  • Nan, Madalina Nicoleta
  • Carretero, Francisco
  • Fernández-Oliva, Antonio
  • Alijotas Reig, Jaume
  • Garrido-Giménez, Carmen
Angiogenic factors; Preeclampsia; Uric acid, Factores angiogénicos; Preeclampsia; Ácido úrico, Factors angiogènics; Preeclàmpsia; Àcid úric, N-terminal pro-brain natriuretic peptide (NT-proBNP) and uric acid are elevated in pregnancies with preeclampsia (PE). Short-term prediction of PE using angiogenic factors has many false-positive results. Our objective was to validate a machine-learning model (MLM) to predict PE in patients with clinical suspicion, and evaluate if the model performed better than the sFlt-1/PlGF ratio alone. A multicentric cohort study of pregnancies with suspected PE between 24+0 and 36+6 weeks was used. The MLM included six predictors: gestational age, chronic hypertension, sFlt-1, PlGF, NT-proBNP, and uric acid. A total of 936 serum samples from 597 women were included. The PPV of the MLM for PE following 6 weeks was 83.1% (95% CI 78.5-88.2) compared to 72.8% (95% CI 67.4-78.4) for the sFlt-1/PlGF ratio. The specificity of the model was better; 94.9% vs. 91%, respectively. The AUC was significantly improved compared to the ratio alone [0.941 (95% CI 0.926-0.956) vs. 0.901 (95% CI 0.880-0.921), p < 0.05]. For prediction of preterm PE within 1 week, the AUC of the MLM was 0.954 (95% CI 0.937-0.968); significantly greater than the ratio alone [0.914 (95% CI 0.890-0.934), p < 0.01]. To conclude, an MLM combining the sFlt-1/PlGF ratio, NT-proBNP, and uric acid performs better to predict preterm PE compared to the sFlt-1/PlGF ratio alone, potentially increasing clinical precision., This work was supported by public funds obtained in competitive calls with peer review (grant PI19/00702), Insituto de Salud Carlos III, Spanish Ministry of Health, by the Maternal and Child Health and Development Network (SAMID, RD16/0022/0015), Instituto de Salud Carlos III, Madrid, Spain, the Spanish Clinical Research and Clinical Trials Platform, SCReN (Spanish Clinical Research Network), funded by the ISCIII-General Subdirectorate for Evaluation and Promotion of Research, through project PT13/0002/0028, integrated in the 2013–2016 R + D + I State Plan and co-financed by and the European Regional Development Fund (FEDER); and by the Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin Network (RICORS, RD21/0012/0001), Instituto de Salud Carlos III, Madrid, Spain, funded by the Recovery, Transformation and Resilience Plan 2017–2020, ISCIII, and by the European Union-Next Generation EU. Dr Cruz-Lemini is supported by Juan Rodés contract JR19/00047, Instituto de Salud Carlos III-Spanish Ministry of Health. Funding sources were not involved in study design, collection, analysis, and interpretation of data.